Bacterin Announces Closing of Public Offering of Common Stock BELGRADE, MT

Announces Closing of Public Offering of Common Stock

BELGRADE, MT, August 6, 2014

-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings

for medical applications, today announced the completion of its previously announced underwritten

public offering of 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common

stock at an exercise price of $7.12 per share to the public. Net proceeds from the offering

were approximately $5.8 million, after deducting underwriting discounts, commissions and other expenses.

Northland Securities, Inc. was the sole book-running

manager for the offering. Copies of the prospectus and prospectus supplement relating to the shares of common stock and warrants

to purchase common stock offered in the offering may be obtained by contacting Northland Securities, Inc. at 45 South Seventh Street,

Suite 2000, Minneapolis, MN 55402, or by calling toll free 800-851-2920, or by e-mail at apafko@northlandcapitalmarkets.com.

The offering was conducted pursuant to an effective

shelf registration statement on file with the Securities and Exchange Commission. A prospectus supplement relating to the offering

was filed with the Securities and Exchange Commission.

This press release shall not constitute an

offer to sell or a solicitation of an offer to buy any securities of Bacterin International Holdings, Inc., and there shall not

be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior

to the registration or qualification under the securities laws of any such state or jurisdiction.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic

and international markets. These products are used in a variety of applications including enhancing fusion in spine surgery, relief

of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral

repair in knee and other joint surgeries.

Bacterin's Medical Device division develops,

employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking

contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation

Reform Act of 1995 that are subject to significant risks and uncertainties, including statements regarding our expectations

with respect to the anticipated use of proceeds of the public offering. Forward-looking statements

include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words

such as "continue," "efforts," "expects," "anticipates," "intends," "plans,"

"believes," "estimates," "projects," "forecasts," "strategy," "will,"

"goal," "target," "prospects," "potential," "optimistic," "confident,"

"likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may

be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and

actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability

to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the

Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's

ability to remain listed on the NYSE MKT; the Company's ability to develop, market, sell and distribute desirable applications,

products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results;

the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as

and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees

with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact

of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors;

and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form

10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any

forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated

events, except as required by law.

Northland Capital Markets is the trade

name for certain capital markets and investment banking services of Northland Securities, Inc., member FINRA/SIPC.